Acute Myeloid Leukemia – Epidemiology – Emerging Markets Data
- The number of incident cases of AML in the countries under study will increase by 43%, from 58,000 to 82,000, in ten years.
- Of the countries considered in this analysis, the incidence of AML is highest in Turkey at 2.4 per 100,000 per year.
- Of all incident cases of AML, 25% have FLT3–ITD and 5% have FLT3–TKD/ disease.
- The average age of all incident cases of AML in the countries under study is 54.
Table of contents
- Acute Myeloid Leukemia - Epidemiology - Emerging Markets Data
- Introduction
- Key Findings
- Overview
- Diagnosed Incidence of Acute Myeloid Leukemia per 100,000 People of All Ages in 2019 and 2029ttttttttttttttttttttt
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Acute Myeloid Leukemia over the Next Ten Yearsttttttttt
- Number of Additional Incident Cases of Acute Myeloid Leukemia Incurred Over 2019-2029 in the Countries Under Studyttttttttt
- Key Findings
- Epidemiology Data
- Methods
- Diagnosed Prevalent Cases
- Diagnosed Incident Cases
- FLT-3 Mutation
- Lifetime DALYs Gained
- Drug-Treatable Populations
- Drug-Treated Populations
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Acute Myeloid Leukemia
- Studies Excluded from the Analysis of Acute Myeloid Leukemia
- Risk/Protective Factors
- Risk/Protective Factors for Acute Myeloid Leukemia
- Bibliography
- Glossary
- Literature Review
- Introduction
Pramilesh Suryawanshi, M.P.H., is an associate epidemiologist at Clarivate. Previously, Mr. Suryawanshi worked with Pathfinder International in Lepra, the Netherlands Leprosy Relief Foundation, and the National Health Mission. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai, where he worked on several public health projects, including the assessment of social health insurance schemes. He holds a bachelor’s degree in the Indian system of medicine (Ayurveda) from Rajiv Gandhi University of Health Sciences in Karnataka.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.